**GI PATHOPHYSIOLOGY COURSE**

**Friday, October 25, 2019 | 7:00 am - 12:30 pm | Stars at Night Ballroom - B2**

**Course Directors:** Darwin L. Conwell, MD, MS, FACP, and Ikuo Hirano, MD, FACP

---

**COURSE DESCRIPTION**

Gain a better understanding of gastrointestinal disease processes and their impact on clinical presentation of patients when you attend the GI Pathophysiology Course. Experts will review the underlying causes and clinical implications of commonly encountered diseases seen in practice.

The course includes discussion of functional genomics, physiologic testing to manage esophageal disorders, celiac disease, biologic therapies for IBD, molecular and genetic testing for colon polyps/cancer, therapeutic approaches to NAFLD, and managing refractory constipation. Lecture presentations will be followed by interactive question and answer sessions. The discussions will be clinically based and will offer points on how to better help patients with difficult-to-manage disease processes. The course faculty are recognized experts in their fields and pioneers in better understanding of the disease processes in gastroenterology. The course is designed primarily for clinicians in GI/hepatology, as well as physician assistants, nurse practitioners, and other advanced practice healthcare professionals interested in the clinical application of GI pathophysiology.

---

**ACCREDITATION / CME / MOC**

The American College of Gastroenterology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Gastroenterology designates this live activity for a maximum of 5.25 **AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

---

**COURSE AGENDA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td>Continental Breakfast</td>
</tr>
<tr>
<td>7:00 am</td>
<td>Welcome and Introductions</td>
</tr>
<tr>
<td></td>
<td>Darwin L. Conwell, MD, MS, FACP, and Ikuo Hirano, MD, FACP</td>
</tr>
<tr>
<td>7:05 am</td>
<td>Functional Genomics and Precision Medicine: What Every Gastroenterologist Should Know</td>
</tr>
<tr>
<td></td>
<td>David C. Whitcomb, MD, PhD, FACP</td>
</tr>
<tr>
<td></td>
<td>Discuss how to use functional genomics and precision medicine to improve patient care and outcomes in gastrointestinal disorders.</td>
</tr>
<tr>
<td>7:45 am</td>
<td>Interpretation and Therapeutic Implications of Physiologic Testing in the Management of Esophageal Disorders</td>
</tr>
<tr>
<td></td>
<td>Ikuo Hirano, MD, FACP</td>
</tr>
<tr>
<td></td>
<td>Identify the pearls and pitfalls in the use of motility, impedance, impedance planimetry, and pH testing in the assessment of patients with esophageal disorders.</td>
</tr>
<tr>
<td>8:25 am</td>
<td>Celiac Disease: Novel Therapeutic Approaches Beyond Gluten Withdrawal</td>
</tr>
<tr>
<td></td>
<td>Peter H. R. Green, MD, FACP</td>
</tr>
<tr>
<td></td>
<td>Explain the mechanisms behind novel diagnostic strategies and pharmacologic approaches for patients with celiac disease.</td>
</tr>
<tr>
<td>9:05 am</td>
<td>Scientific Basis of Novel Immunologic Approaches to IBD</td>
</tr>
<tr>
<td></td>
<td>Anita Afzali, MD, MPH, FACP</td>
</tr>
<tr>
<td></td>
<td>Apply concepts regarding the immunologic basis of novel biologic therapies to the management of IBD.</td>
</tr>
<tr>
<td>9:45 am</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Break</td>
</tr>
<tr>
<td>10:15 am</td>
<td>How to Apply Molecular and Genetic Testing to Colon Polyps and Cancer Management</td>
</tr>
<tr>
<td></td>
<td>Elena M. Stoffel, MD, MPH</td>
</tr>
<tr>
<td></td>
<td>Formulate an approach to the use of molecular and genetic testing in the evaluation and management of colon polyps and cancer.</td>
</tr>
<tr>
<td>10:55 am</td>
<td>Physiologic Basis of Current and Future Approaches to Non-Alcoholic Fatty Liver Disease</td>
</tr>
<tr>
<td></td>
<td>Zobair M. Younossi, MD, MPH, FACP</td>
</tr>
<tr>
<td></td>
<td>Develop a conceptual framework for the appropriate utilization of novel therapeutics for fatty liver diseases.</td>
</tr>
<tr>
<td>11:35 am</td>
<td>Mechanistic Underpinnings for the Management of Refractory Constipation</td>
</tr>
<tr>
<td></td>
<td>Darren M. Brenner, MD</td>
</tr>
<tr>
<td></td>
<td>Apply concepts regarding the physiologic basis of constipation to inform therapeutic decisions for patients with refractory constipation.</td>
</tr>
<tr>
<td>12:15 pm</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>GI Pathophysiology Course Adjourns</td>
</tr>
</tbody>
</table>
FACULTY LISTING AND DISCLOSURE INFORMATION

The American College of Gastroenterology (ACG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ACG, as an ACCME accredited provider, ensures balance, independence, objectivity, and scientific rigor in all of its directly and jointly provided education activities. All who are in a position to control the content of an education activity (including their spouse or partner) are required to disclose to ACG all relevant financial relationships in any amount occurring in the past 12 months with any commercial interest that may create a conflict of interest related to the subject matter of an education activity. Safeguards against commercial bias have been put in place by ACG. Anyone who refuses to disclose relevant financial relationships will be disqualified. ACG ensures any conflicts of interest are resolved before the educational activity occurs and discloses all relevant financial relationships to the learners prior to the beginning of an education activity.

ACG staff involved with this activity have nothing to disclose. Faculty have noted the following relationships related to their GI Pathophysiology Course presentations.

COURSE DIRECTORS

Darwin L. Conwell, MD, MS, FACG
Professor of Medicine; Director, Division of Gastroenterology, Hepatology and Nutrition, Ohio State University Wexner Medical Center, Columbus, OH
Dr. Conwell has indicated no relevant financial relationships.

Ikuo Hirano, MD, FACG
Professor of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
Consultant: Adare, Allakos, Receptos, Regeneron, Shire

FACULTY

Anita Afzali, MD, MPH, FACG
Medical Director, Inflammatory Bowel Disease Center, The Ohio State University Wexner Medical Center, Columbus, OH
Advisory Committee/Board Member: AbbVie, Celgene, IBD Horizons, Janssen, Takeda, UCB
Consultant: AbbVie, Celgene, IBD Horizons, Janssen, Pfizer, Takeda, UCB
Grant/Research Support: AbbVie, Celgene, Janssen, Takeda
Speakers Bureau: AbbVie, Janssen, Pfizer, Takeda, UCB

Darren M. Brenner, MD
Associate Professor of Medicine and Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL
Advisory Committee/Board Member: Allergan Pharmaceuticals, Ironwood, Salix/Valeant Pharmaceuticals
Consultant: Allergan Pharmaceuticals, Ironwood, Salix/Valeant Pharmaceuticals
Speakers Bureau: Allergan Pharmaceuticals, Ironwood, Salix/Valeant Pharmaceuticals

Peter H. R. Green, MD, FACG
Phyllis & Ivan Seidenberg Professor of Medicine, Columbia University, New York, NY
Advisory Committee/Board Member: Celimmune, ImmunogenX, ImmusantT, Janssen

Ikuko Hirano, MD, FACG
Professor of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
Dr. Hirano has indicated no relevant financial relationships.

Elena M. Stoffel, MD, MHP
Assistant Professor of Internal Medicine; Director, Cancer Genetics Clinic, University of Michigan Medical School, Ann Arbor, MI
Dr. Stoffel has indicated no relevant financial relationships.

David C. Whitcomb, MD, PhD, FACG
Professor, Medicine/GI, University of Pittsburgh, Pittsburgh, PA
Advisory Committee/Board Member: Ariel Precision Medicine
Consultant: Ariel Precision Medicine
Patent Holder: Ariel Precision Medicine
Stockholder/Ownership Interest (excluding diversified mutual funds): Ariel Precision Medicine
Co-Founder: Ariel Precision Medicine

Zobair M. Younossi, MD, MPH, FACG
Chairman, Department of Medicine, Inova Fairfax Medical Campus;
Professor of Medicine, Virginia Commonwealth University, Inova Campus;
Affiliate Professor of Biomedical Sciences, George Mason University, Inova Health System, Washington, DC
Consultant: AbbVie, BMS, Gilead, Intercept, Merck, Novartis, Novo Nordisk, Shionogi, Terns, Viking

PEER REVIEW SUBCOMMITTEE MEMBERS

To resolve identified conflicts of interest, the educational content was peer reviewed by the Course Director or a member of the ACG Educational Affairs Peer Review Subcommittee.

Scott L. Gabbard, MD (Chair), Cleveland, OH
Dr. Gabbard has indicated no relevant financial relationships.

Steven L. Carpenter, MD, FACG, Savannah, GA
Dr. Carpenter has indicated no relevant financial relationships.

John O. Clarke, MD, Stanford, CA
Dr. Clarke has indicated no relevant financial relationships.

Steven L. Flamm, MD, FACG, Chicago, IL
Dr. Flamm has indicated no relevant financial relationships.

Aaron S. Goldberg, MD, Phoenix, AZ
Dr. Goldberg has indicated no relevant financial relationships.

Edith Y. Ho, MD, MS, FACG, Cleveland, OH
Dr. Ho has indicated no relevant financial relationships.

Shivangi T. Kothari, MD, FACG, Rochester, NY
Dr. Flamm has indicated no relevant financial relationships.

Renee L. Young, MD, FACG, Omaha, NE
Dr. Young has indicated no relevant financial relationships.